Nanosphere’s Test FDA Approved and 4 Stocks that Have Hit 52-Week Highs

Grand Canyon Education (NASDAQ:LOPE): New college grads will be required to begin paying interest on subsidized student loans very soon after graduation, even if Congress does complete an arrangement that side-steps the doubling of the interest rates on the loans in July, reports The Washington Post. Student loan recipients were previously allowed to wait six months before interest payments, but that is gone with the new rules, along with graduate students being eligible for the loans. Estimates have it that the new squeeze on interest payments will amount to an added $18 billion over the next decade. Grand Canyon shares closed up 2.15 percent on the day at $20.45, having been traded between $13.71 and $20.20 the last 52 weeks.

Don’t Miss: Early Movers: Facebook SINKS, Arena REVERSES.

Mccormick & Company’s (NYSE:MKC) second quarter earnings conference call revealed that its fiscal year 2012 share buybacks are expected to be even with those of 2011, and material cost rises in the high single digits; gross profit margin is projected to stabilize in the second half, after a first quarter slump and a second quarter comparable result. Shares closed up on the day by 2.91 percent at $59.09, having traded between $43.36 to $59.24 over the past 52 weeks.

Nanosphere’s (NASDAQ:NSPH) Verigene GP Blood Culture Nucleic Acid Test has been okayed for marketing by the FDA, and is the first such test that can sort out 12 different bacterial types known to cause bloodstream infections. More specifically, this test provides simultaneous identification of the bacteria and three associated resistance genes only a few hours subsequent to the first sign of bacterial growth, and can identify different types of Staphylococcus, Streptococcus, Enterococcus, and Listeria. Nanosphere shares closed up 21.47 percent on the day at $2.32, having traded during the last 52 weeks between 89 cents and $2.41.

News Corp. (NASDAQ:NWSA) is being counseled by Goldman Sachs, JPMorgan and Centerview Partners, as it looks at how it might break itself up, say inside sources to Bloomberg, which also report that JPMorgan is working with News Corp. on the capital structure, credit ratings and financing for the publishing company side. Shares closed at $22.31 which represents a 2.53 percent rise on the day, having been traded for thw past 52 weeks between $13.38 and $21.89.

Orexigen Therapeutic (NASDAQ:OREX) and VIVUS (NASDAQ:VVUS) shares pop in tandem with those of Arena (NASDAQ:ARNA), following the FDA approval of the latter’s diet med. OREX shares closed up 20.29 percent on the day at $4.92, having traded between $1.22 and $5.14 in a 52-week range.

Don’t Miss: ARENA SHARES EXPLODE! First U.S. Diet Drug Approved in 13 Years.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.